HEALTHCARE DEAL ADVISORY

Where healthcare deals get done.

Crimson Ridge Partners is a healthcare deal advisory firm focused on creating value through high-impact transactions across sectors, including pharmaceuticals, biologics, medical devices and digital health.

We are not generalist advisors; we are focused solely on healthcare. In a complex and rapidly evolving industry, Crimson Ridge Partners delivers clarity, momentum, and results when transactions matter most.

Healthcare only

Focused exclusively on pharmaceutical and healthcare transactions.

Decades of experience

Combined 50 years of healthcare leadership across markets and business models.

Cross-border reach

Europe, Middle East and Africa, and South-East Asia. Selected support available for Americas and Asia-Pacific.

Partner-led throughout

Direct senior involvement from mandate definition to closing.

FOCUS AREAS

Mandates built around transactions, not generic advice.

We combine strategic judgment, opportunity origination and transaction execution within a single senior-led mandate.

I.

Portfolio strategy and asset sourcing

II.

Licensing and distribution

III.

Acquisitions and divestments

IV.

Commercial strategy and market entry

V.

Strategic transactions

OUR APPROACH

One accountable lead partner from start to finish.

Mandate definition
and scoping

1

Target identification
and prioritization

2

Outreach and
screening

3

Due diligence and
structuring

4

Signing and
closing


5




WHERE WE OPERATE

Healthcare expertise across sectors and borders.

Pharmaceuticals
(Rx, OTC, VAM/505b2)

Biologics
(incl. biosimilars)

Medical
devices

Digital health
solutions

Healthcare
services

Geographic reach

  • Headquartered in Dubai, U.A.E.

  • Focus on Europe, Middle East and Africa, and South-East Asia

  • Selected mandate support available for Americas and Asia-Pacific

  • Established relationships and expertise across developed and emerging markets


Advisors first.
Dealmakers second.
Partners always.

NEXT STEP

Reviewing your commercial or portfolio strategy?

Considering a licensing opportunity, acquisition or strategic partnership?

Evaluating an expansion into new markets, channels or therapeutic areas?

Speak directly with the partners about the opportunity, the market and the practical path forward.